Bicara Therapeutics Inc. (BCAX) Stock Analysis

Q: What is the BCAX stock price target?

Take-profit $26.54 (+23.6% upside). Prior stop was $19.98.

Q: Is BCAX overvalued or undervalued?

Bicara Therapeutics Inc. trades at a P/E of N/A (forward -7.0). TrendMatrix value score: 7.5/10. Overall verdict: Sell.

Q: What do analysts say about BCAX?

20 analysts cover BCAX with a consensus score of 4.1/5. Average price target: $31.

SellModerate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

$21.56+23.6% A.UpsideScore 4.8/10#101 of 158 Biotechnology

Stop $19.98Target $26.54(analyst − 13%)A.R:R 2.8:1

Analyst target$30.50+41.5%12 analysts

$26.54our TP

$21.56price

$30.50mean

$16

$48

Sell if holding. Engine safety override at $21.56: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 2.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.8/10, moderate confidence.

Passes 4/7 gates (favorable risk/reward ratio, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and clean insider activity. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Quality below floor (1.6 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-7.0

Mkt Cap$1.4B

EV/EBITDA-6.3

Profit Mgn0.0%

ROE-30.9%

Rev Growth—

Beta—

DividendNone

Rating analysts20

Quality Signals

Piotroski F4/9

Options Flow

P/C0.64bullish

IV98%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value7.515%1.13

Quality1.615%0.24

Growth5.015%0.75

Momentum2.510%0.25

Sentiment6.510%0.65

Insider Activity5.710%0.57

Peer Rank5.510%0.55

Technical Setup7.15%0.35

Risk Profile3.55%0.18

Catalyst2.55%0.13

Overall (Σ contributions)4.79

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

4.4

Current Ratio

5.0

Moat

5.0

Cash-burning (FCF negative)No competitive moatQuality concerns

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd

0.0

Volume

0.0

Obv

1.0

Rsi

5.5

Ma Position

6.0

Volume distribution (falling OBV)Above 200-day MA

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History

0.0

Surprise Avg

0.0

Erm

5.0

Earnings Timing

5.0

Earnings concerns: 1B/3MEarnings in 12 days

GatesMomentum 2.5<4.5INSIDER 2.60%=EXTREMEEARNINGS PROXIMITY 12d<=14d (soft)A.R:R 2.8 ≥ 1.5No SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Aggressive

RSI

53 · Neutral

↓ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $19.92Resistance $24.25

Price Targets

$20

$27

A.Upside+23.1%

A.R:R2.8:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.6 < 4.0)

! Momentum score 2.5/10 — below 4.5 minimum

! Insider activity: 2.60%=extreme

Earnings

1/4 beats

Next Earnings2026-05-12 (12d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is BCAX stock a buy right now?

Sell if holding. Engine safety override at $21.56: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 2.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $19.98. Score 4.8/10, moderate confidence.

What is the BCAX stock price target?

Take-profit target: $26.54 (+23.6% upside). Prior stop was $19.98. Stop-loss: $19.98.

What are the risks of investing in BCAX?

Quality below floor (1.6 < 4.0).

Is BCAX overvalued or undervalued?

Bicara Therapeutics Inc. trades at a P/E of N/A (forward -7.0). TrendMatrix value score: 7.5/10. Verdict: Sell.

What do analysts say about BCAX?

20 analysts cover BCAX with a consensus score of 4.1/5. Average price target: $31.

What does Bicara Therapeutics Inc. do?Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional...

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.